Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Common Equity (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Common Equity for 17 consecutive years, with $10.7 million as the latest value for Q1 2026.

  • Quarterly Common Equity rose 3.88% to $10.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.7 million through Mar 2026, up 3.88% year-over-year, with the annual reading at $21.5 million for FY2025, 2.96% up from the prior year.
  • Common Equity for Q1 2026 was $10.7 million at Achieve Life Sciences, down from $21.5 million in the prior quarter.
  • The five-year high for Common Equity was $49.5 million in Q1 2024, with the low at -$1.4 million in Q4 2023.
  • Average Common Equity over 5 years is $18.7 million, with a median of $13.2 million recorded in 2022.
  • The sharpest move saw Common Equity plummeted 117.44% in 2023, then soared 11063.88% in 2024.
  • Achieve Life Sciences' Common Equity stood at $8.3 million in 2022, then plummeted by 117.44% to -$1.4 million in 2023, then surged by 1543.3% to $20.9 million in 2024, then grew by 2.96% to $21.5 million in 2025, then plummeted by 50.38% to $10.7 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Common Equity are $10.7 million (Q1 2026), $21.5 million (Q4 2025), and $33.6 million (Q3 2025).